Menu

The Scientist Staff

Infographic: How to Predict If a Species Is At Risk

To calculate the likelihood that organisms will be harmed by climate change, researchers estimate their exposure, sensitivity, and ability to adapt to new conditions.

Jul 1, 2018
Catherine Offord

Researchers use various methods to estimate a species’ vulnerability to climate change. One popular class of assessments takes a trait-based approach, calculating organisms’ vulnerability on the basis of their exposure to climate change, their sensitivity to that change, and their potential to adapt to new conditions, termed their adaptive capacity.

Sensitivity

A measure of how likely a species is to experience negative effects of climate change. Failing to account for traits that confer higher sensitivity can result in overoptimistic estimates of species’ vulnerability.

Adaptive Capacity

The potential for species and populations to temporarily escape the negative effects of climate change via natural selection or individual plasticity.

Exposure

The magnitude and type of environmental changes that a population is likely to experience under future climate scenarios. Estimates of exposure are strongly affected by the choice of climate forecast model, and add a considerable source of uncertainty into climate change vulnerability assessments.

Read the full story.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.